Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment

Authors :: Chunyan Ji
Feng Chen
Lizhen Li
Daoxin Ma
Ming Hou
Maohong Zhang
Shuxin Yan
Jian-zhi Sun
Source :: Leukemia Research. 34:e75-e77
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Cancer Research
business.industry
Imatinib
Hematology
Philadelphia chromosome
medicine.disease
chemistry.chemical_compound
Myelogenous
Leukemia
Imatinib mesylate
Oncology
chemistry
medicine
Cancer research
Neoplasm
Indirubin
business
Derivative (chemistry)
medicine.drug

Tools